Michel Samaha, MD
Pulmonary Disease · Milford, DENPI 1346206661
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $83,287 of the $94,325 with a category attached, or 88.3%. GSK accounts for 78.4% of it on its own, with 32 other manufacturers making up the rest. Reporting peaked in 2023 at $49,700 and has fallen 97.3% since, to $1,325 in 2025. Among pulmonary disease clinicians in DE with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 381 payments — averaging $247.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$74K
- Mylan Specialty L.p.$14K
- AstraZeneca$3K
- Sanofi$776
- Insmed, Inc.$467
- Mallinckrodt Hospital Products Inc.$412
- plus $2K from 27 others
What the payments were for
- Speaking & faculty fees$83,28788%
- Travel & lodging$2,0832%
- Food & beverage$8,6789%
- Education$2770%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 98 | $73,968 |
| Mylan Specialty L.p. | 33 | $14,004 |
| AstraZeneca | 85 | $2,546 |
| Sanofi | 37 | $776 |
| Insmed, Inc. | 18 | $467 |
| Mallinckrodt Hospital Products Inc. | 14 | $412 |
| Regeneron Healthcare Solutions, Inc. | 9 | $330 |
| Jazz Pharmaceuticals Inc. | 6 | $278 |
| Boehringer Ingelheim | 14 | $239 |
| ANI Pharmaceuticals, Inc. | 8 | $141 |
| Viatris Specialty LLC | 5 | $104 |
| Sanofi-aventis U.S. LLC | 1 | $99 |
| Advanced Respiratory, Inc | 5 | $94 |
| Grifols USA, LLC | 6 | $91 |
| Axsome Therapeutics, Inc. | 4 | $81 |
| Philips North America LLC | 5 | $77 |
| Mallinckrodt Enterprises LLC | 4 | $71 |
| Lilly USA, LLC | 3 | $68 |
| Tactile Systems Technology Inc | 2 | $54 |
| Merck | 2 | $47 |
| Covidien LP | 3 | $46 |
| Actelion Pharmaceuticals US, Inc. | 2 | $43 |
| Baxter Healthcare | 2 | $42 |
| Novartis | 2 | $40 |
| Amgen | 2 | $39 |
| Verona Pharma, Inc. | 2 | $38 |
| Circassia Inc. | 2 | $31 |
| Electromed, Inc. | 2 | $23 |
| Viiv Healthcare Company | 1 | $16 |
| Gilead | 1 | $15 |
| Genentech USA, Inc. | 1 | $15 |
| United Therapeutics Corporation | 1 | $14 |
| Pfizer | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$94,325 in reported general payments places this provider in the 90th percentile of 39 pulmonary disease providers in Delaware.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 672 | $717,139 |
| Breo ElliptaFluticasone/Vilanterol | 368 | $242,739 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 195 | $168,063 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 133 | $163,248 |
| Arnuity ElliptaFluticasone Furoate | 323 | $107,108 |
| Spiriva HandihalerTiotropium Bromide | 77 | $75,792 |
| TezspireTezepelumab-Ekko | 13 | $54,305 |
| Dupixent SyringeDupilumab | 13 | $48,647 |
| Spiriva RespimatTiotropium Bromide | 51 | $46,771 |
| Dupixent PenDupilumab | 13 | $46,251 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 59 | $38,556 |
| Incruse ElliptaUmeclidinium Bromide | 48 | $36,246 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 741 | $27,681 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 108 | $24,407 |
| Advair HfaFluticasone Propion/Salmeterol | 36 | $21,507 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Arnuity Ellipta, Incruse Ellipta | $73,968 | $1,271,2971,606 claims |
| AstraZenecaBreztri Aerosphere, Tezspire, Bevespi Aerosphere, Symbicort, Pulmicort Flexhaler | $2,546 | $256,020237 claims |
| Boehringer IngelheimSpiriva Respimat, Combivent Respimat, Stiolto Respimat | $239 | $106,340129 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 39 pulmonary disease providers in Delaware.
Other pulmonary disease in Milford
- Victor BanzonLewes$300K
- Albert RizzoNewark$162K
- Haroon RajaNewark$44K
- Ismael MatusNewark$27K
- Vikas BatraLewes$17K
- Ercilia AriasLewes$11K
- David JawaharDover$9K
- Samih RaadLewes$9K
- Anthony VasileWilmington$4K
- Margarita GianniosisDover$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.